Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s12288-013-0240-9 http://scihub22266oqcxt.onion/10.1007/s12288-013-0240-9 C4022918!4022918!24839361     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Indian+J+Hematol+Blood+Transfus 2014 ; 30 (2): 85-90 Nephropedia Template TP {{tp|p=24839361|t=2014. Rational Use of Recombinant Factor VIIa in Clinical Practice |pdf=|usr=}}{{24839361}} gab.com Text Rational Use of Recombinant Factor VIIa in Clinical Practice JO: Indian J Hematol Blood Transfus http://www.kidney.de/pget.php?&tw=1&pmid=24839361 #FOAvip In the United States, the FDA-approved indications for recombinant factor VIIa is for bypassing inhibitors to factors VIII and IX in patients with hemophilia A and B respectively and for treatment of congenital factor VII deficiency. In European countries, rFVIIa is licensed for the above indications as well as for Glanzmann?s thrombasthenia. In absence of high-quality data favoring off-label use of this agent and laboratory test to predict response to this agent, and in view of high cost of rFVIIa, off-label use of recombinant factor VIIa should be restricted to only when hemorrhage has not responded to transfusion or other conventional therapy. It appears, two such conditions where recombinant factor VIIa may be beneficial are traumatic and postpartum hemorrhages. Twit Text FOAVip Rational Use of Recombinant Factor VIIa in Clinical Practice ????Indian J Hematol Blood Transfus http://www.kidney.de/pget.php?&tw=1&pmid=24839361 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24839361 #FOAvip English Wikipedia <ref>{{Cite pmid|24839361}}</ref> Rational Use of Recombinant Factor VIIa in Clinical Practice #MMPMID24839361 Dutta TK; Verma SP Indian J Hematol Blood Transfus 2014[Jun]; 30 (2): 85-90 PMID24839361show ga In the United States, the FDA-approved indications for recombinant factor VIIa is for bypassing inhibitors to factors VIII and IX in patients with hemophilia A and B respectively and for treatment of congenital factor VII deficiency. In European countries, rFVIIa is licensed for the above indications as well as for Glanzmann?s thrombasthenia. In absence of high-quality data favoring off-label use of this agent and laboratory test to predict response to this agent, and in view of high cost of rFVIIa, off-label use of recombinant factor VIIa should be restricted to only when hemorrhage has not responded to transfusion or other conventional therapy. It appears, two such conditions where recombinant factor VIIa may be beneficial are traumatic and postpartum hemorrhages. äRational Use of Recombinant Factor VIIa in Clinical Practice (epmc).pdf DeepDyve Pubget Overpricing